Arteriosclerosis
Not yet recruitingStudy of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)
- Disease:Arteriosclerosis
- Substances:–
Germany- Participants:18–64 years · 65+ years
- Sponsor:Amgen Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany29 clinical trials in Elsterwerda, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyThe busiest research cities in the country
What the registry says about research in the country
Clinical investigations focusing on weight management and Type 2 Diabetes treatments, evaluating innovative therapies for improved metabolic outcomes.
Studies combining lifestyle modifications with novel therapeutic approaches for comprehensive metabolic health improvement.
Research targeting atherosclerotic cardiovascular disease and innovative treatments for various forms of heart failure.
Comprehensive evaluation of new therapeutic agents for both preserved and reduced ejection fraction heart failure.
Advanced clinical research examining treatments for resistant hypertension and atrial fibrillation, focusing on innovative therapeutic approaches.
Evaluating next-generation medications for better control of complex cardiovascular conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.